Mn Services Vermogensbeheer B.V. Reduces Stock Position in Boston Scientific Co. (NYSE:BSX)

Mn Services Vermogensbeheer B.V. lessened its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 540,300 shares of the medical equipment provider's stock after selling 38,400 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Boston Scientific were worth $54,505,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BSX. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the period. Union Bancaire Privee UBP SA acquired a new position in Boston Scientific in the fourth quarter valued at about $33,074,000. Empowered Funds LLC lifted its stake in Boston Scientific by 13.7% in the fourth quarter. Empowered Funds LLC now owns 26,615 shares of the medical equipment provider's stock valued at $2,377,000 after buying an additional 3,202 shares during the period. Entropy Technologies LP acquired a new position in Boston Scientific in the fourth quarter valued at about $214,000. Finally, Van ECK Associates Corp lifted its stake in Boston Scientific by 1.9% in the fourth quarter. Van ECK Associates Corp now owns 58,984 shares of the medical equipment provider's stock valued at $5,268,000 after buying an additional 1,090 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president now directly owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer now directly owns 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,970 shares of company stock valued at $42,406,693. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. Robert W. Baird increased their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Evercore ISI increased their price target on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Citigroup reissued a "buy" rating and set a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Twenty-one research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $116.00.

Boston Scientific Stock Performance

Shares of BSX stock traded up $1.04 during trading on Friday, hitting $99.60. The company's stock had a trading volume of 10,330,779 shares, compared to its average volume of 6,574,434. The company has a market cap of $147.35 billion, a PE ratio of 79.68, a P/E/G ratio of 2.79 and a beta of 0.68. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The business has a fifty day moving average of $101.03 and a 200-day moving average of $98.74. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.56 earnings per share. As a group, research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.